{
    "clinical_study": {
        "@rank": "120828", 
        "arm_group": [
            {
                "arm_group_label": "Elderly", 
                "arm_group_type": "Experimental", 
                "description": "TD-1211 Dose 1"
            }, 
            {
                "arm_group_label": "Younger", 
                "arm_group_type": "Experimental", 
                "description": "TD-1211 Dose 2"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to measure the way in which TD-1211 is absorbed and eliminated\n      by the body and to evaluate whether it is safe and well tolerated."
        }, 
        "brief_title": "TD-1211 Single-Dose Study in Elderly and Young Healthy Subjects", 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": "Constipation", 
        "condition_browse": {
            "mesh_term": "Constipation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  For the elderly cohort, nonsmoking 65 to 85 years, inclusive.  For the young cohort,\n             nonsmoking 18 to 45 years, inclusive.\n\n          -  Body mass index (BMI) should be 18 to 36 kg/m2, inclusive.\n\n          -  At screening, sitting or supine heart rate of 50 to 100 beats per minute and sitting\n             or supine systolic and diastolic blood pressure of 90 to 150 mm Hg and 50 to 90 mm\n             Hg, respectively (2 of 3 measurements)\n\n          -  Subjects with mild, chronic, stable disease (e.g., controlled hypertension,\n             non-insulin-dependent diabetes, arthritis) may be enrolled if deemed medically\n             acceptable by the investigator\n\n          -  Negative for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus\n             antibody within the last 3 months\n\n          -  No clinically relevant abnormalities in laboratory evaluations\n\n        Exclusion Criteria:\n\n          -  History or presence of clinically significant respiratory, gastrointestinal, renal,\n             hepatic, endocrine, hematological, neurological (including chronic headache, current\n             or prior psychiatric disease/condition, stroke), cardiovascular, psychiatric,\n             musculoskeletal, genitourinary, immunological, or dermatological disorders.  Subjects\n             with mild, chronic, stable disease (e.g., controlled hypertension, controlled\n             hypercholesterolemia, non insulin-dependent diabetes, osteoarthritis) may be enrolled\n             if condition is well controlled and not anticipated to interfere with the objectives\n             of the study.\n\n          -  Any clinically significant abnormal ECG (electrocardiogram).\n\n          -  Participation in another clinical trial of an investigational drug or medical device\n             within 60 days.\n\n          -  Donation of \u2265500 mL blood, or equivalent, within 8 weeks prior to admission day.\n\n          -  Any other condition that, in the opinion of the investigator, would confound or\n             interfere with evaluation of safety, tolerability, or PK of the investigational drug\n             or prevent compliance with the study protocol."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "47", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01655771", 
            "org_study_id": "0083"
        }, 
        "intervention": [
            {
                "arm_group_label": "Elderly", 
                "intervention_name": "TD-1211 Dose 1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Younger", 
                "intervention_name": "TD-1211 Dose 2", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Opioid induced constipation", 
            "Constipation"
        ], 
        "lastchanged_date": "May 23, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Antonio", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78209"
                }, 
                "name": "ICON Development Solutions"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1, Open-Label, Single-Dose, Parallel-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of TD-1211 Administered Orally to Elderly and Young Healthy Subjects", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Cmax", 
                "safety_issue": "No", 
                "time_frame": "0-96 hours"
            }, 
            {
                "measure": "AUCt", 
                "safety_issue": "No", 
                "time_frame": "Based on samples collected 0-96 hours"
            }, 
            {
                "measure": "AUCinf", 
                "safety_issue": "No", 
                "time_frame": "Based on samples collected 0-96 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01655771"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of patients with treatment-emergent adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Days 1-14"
            }, 
            {
                "measure": "Number patients with abnormal vital sign measurements", 
                "safety_issue": "Yes", 
                "time_frame": "Days 1-5"
            }, 
            {
                "measure": "Number of patients with abnormal clinical laboratory results", 
                "safety_issue": "Yes", 
                "time_frame": "Days 1-5"
            }, 
            {
                "measure": "Number of patients with abnormal corrected QTc interval", 
                "safety_issue": "Yes", 
                "time_frame": "Days 1-5"
            }
        ], 
        "source": "Theravance, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Theravance, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}